NewcelX opened higher at $2.92, compared with its previous close of $2.80. In the last trading session, the stock traded between $2.71 and $2.98. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in NewcelX is now worth
$ 37.86
Resulting in a loss of
$ 62.14 (62.14%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.04 (-1.43%)
Day High
$2.98
Day Low
$2.71
Day Open
$2.92
Prev Close
$2.80
Volume
11,870
1W Return
6.69%
1M Return
-6.60%
3M Return
-14.15%
6M Return
-17.61%
1Y Return
-26.40%
Fundamentals
Market Cap ($ Mn)
15
PE Ratio
-
PB Ratio
2.11
PEG Ratio
-
ROE
-
ROCE
50.61%
EPS (TTM)
-
Investment Returns
1 Week
6.69%
1 Month
-6.60%
3 Months
-14.15%
6 Months
-17.61%
9 Months
0.00%
Financials
Quarterly
All values in $ Mn
0.0
Mar 20
0.0
Jun 20
Updates
31Jul
NewcelX prices $1.4M equity financing at 20% premium to fund NCEL-101
NewcelX Ltd. announced the pricing of a $1.4 million private placement involving 347,134 common shares and warrants at $4.033 per share, representing a 20% premium to the previous closing price. The warrants allow purchase at $4.437. Funds will support the advancement of its lead program, NCEL-101, in collaboration with Eledon Pharmaceuticals.
3mo ago
13Jul
Laidlaw & Co. initiates coverage on NewcelX with Buy rating
Laidlaw & Co. analyst Yale Jen has initiated coverage on NewcelX (NASDAQ: NCEL) with a Buy rating and a price target of $23. The positive rating reflects the firm's confidence in the company's growth potential.
4mo ago
8Jul
NewcelX appoints Dr. Camillo Ricordi to Scientific Advisory Board
NewcelX Ltd. has appointed Dr. Camillo Ricordi to its Scientific Advisory Board to support the advancement of its type 1 diabetes program and collaboration with Eledon Pharmaceuticals. This follows a successful FDA Type B Pre-IND meeting for NCEL-101, which established a clear regulatory pathway for clinical trials combining NCEL-101 with tegoprubart.
4mo ago
15Jun
NewcelX study validates AstroRx therapy for multiple sclerosis
NewcelX announced the publication of a peer-reviewed study in Stem Cell Reports validating AstroRx, a human embryonic stem cell-derived astrocyte therapy, for its potential in treating multiple sclerosis. The study demonstrated that AstroRx addresses key barriers to remyelination by enhancing myelin debris clearance, sustaining a pro-repair inflammatory environment, and promoting the differentiation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes. These effects were observed both in-vitro and in an in-vivo lysolecithin-induced demyelination model.
